Inhibrx’s (INBX) “Market Perform” Rating Reiterated at JMP Securities

JMP Securities reissued their market perform rating on shares of Inhibrx (NASDAQ:INBX) in a report issued on Wednesday morning,Benzinga reports.

Inhibrx Trading Up 0.5 %

NASDAQ INBX opened at $13.15 on Wednesday. Inhibrx has a 52 week low of $10.80 and a 52 week high of $18.95. The company has a 50 day moving average price of $14.62 and a 200 day moving average price of $14.65.

Insider Activity

In other Inhibrx news, Director Jon Faiz Kayyem purchased 69,686 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were acquired at an average price of $14.23 per share, for a total transaction of $991,631.78. Following the completion of the purchase, the director now owns 51,093 shares of the company’s stock, valued at approximately $727,053.39. The trade was a -374.80 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 22.20% of the company’s stock.

Institutional Trading of Inhibrx

Institutional investors have recently bought and sold shares of the stock. Exchange Traded Concepts LLC acquired a new position in Inhibrx during the 4th quarter valued at approximately $148,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Inhibrx in the 4th quarter valued at $348,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Inhibrx in the 4th quarter valued at $47,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.